Journal article

Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group

Lisa Pleyer, Hartmut Doehner, Herve Dombret, John F Seymour, Andre C Schuh, CL Beach, Arlene S Swern, Sonja Burgstaller, Reinhard Stauder, Michael Girschikofsky, Heinz Sill, Konstantin Schlick, Josef Thaler, Britta Halter, Sigrid Machherndl Spandl, Armin Zebisch, Angelika Pichler, Michael Pfeilstoecker, Eva M Autzinger, Alois Lang Show all

International Journal of Molecular Sciences | MDPI | Published : 2017

Grants

Funding Acknowledgements

The authors would like to acknowledge and thank Lucinda Huxley from FireKite, an Ashfield company, part of UDG Healthcare plc, for proofreading as an English native speaker, as well as editing of the references and figures to the required journal format. She had no influence on planning the study, interpreting the data, the writing or content of the manuscript, nor the decision to submit. Editorial assistance was funded by Celgene. The Austrian Azacitidine Registry (AAR) is a Registry of the Arbeitsgemeinschaft Medikamentose Tumortherapie (AGMT) Study Group, which served as the responsible sponsor and holds the full and exclusive rights to data. Financial support for the AGMT was provided by Celgene. Celgene had no role in the study design, data collection, data analysis, data interpretation, writing of the manuscript, nor the decision to submit the manuscript for publication. The Austrian Azacitidine Registry is a registry of the AGMT Study Group, which served as the responsible sponsor and holds the full and exclusive rights to data. Financial support for the AGMT was provided by Celgene. The AZA-AML-001 trial was supported by research funding from Celgene Corporation, Summit, NJ, USA. Editorial assistance (proofreading by an English native speaker and editing of the references and figures to the required journal format) was funded by Celgene. The funding bodies had no role in the study design, data collection, data analysis, data interpretation, writing of the manuscript, nor the decision to submit the manuscript for publication.